Regor Therapeutics Group, a US-based biotech with significant ties to China, has entered into a licensing agreement with Genentech, a subsidiary of Swiss pharmaceutical giant Roche (SWX: ROG; OTCMKTS: RHHBY) . Under the agreement, Genentech will acquire the rights to develop, manufacture, and commercialize Regor’s next-generation CDK inhibitors, including the Phase I candidate RGT-419B for the treatment of breast cancer, for an upfront payment of USD 850 million. The deal also includes potential future payments based on undisclosed milestones .
RGT-419B is designed to be a potent CDK4 inhibitor with additional activity against CDK2 and selectivity against CDK6, which may overcome resistance and reduce hematologic toxicity. The molecule has shown promising results in Phase I trials, with a favorable safety profile and preliminary signs of efficacy as a monotherapy in patients with advanced breast cancer who have failed prior CDK4/6 inhibitor treatments .
Regor, which operates out of Boston, Massachusetts, and Shanghai, China, was founded in July 2018 with Series A funding from Qilu Pharmaceutical Group. The company’s pipeline includes innovative drug candidates in oncology, metabolism, and auto-immunity, with RGT-419B at the forefront of its oncology programs .- Flcube.com
